Compounds > naltrexone

naltrexone and 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan

naltrexone has been researched along with 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ferguson, DM; Metzger, TG; Paterlini, MG; Portoghese, PS1
Aschenbach, LC; He, H; Li, G; Selley, DE; Zhang, Y1
Burgman, M; Grinnell, S; Haselton, N; Majumdar, S; Ocampo, J; Pasternak, AR; Pasternak, GW1
Beletskaya, IO; Elbegdorj, O; Selley, DE; Yuan, Y; Zhang, Y1
Arnatt, CK; He, H; Kellogg, GE; Mosier, PD; Selley, DE; Zaidi, SA; Zhang, Y1

Other Studies

5 other study(ies) available for naltrexone and 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan

ArticleYear
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
    Journal of medicinal chemistry, 2001, Mar-15, Volume: 44, Issue:6

    Topics: Amino Acid Sequence; Base Sequence; Binding, Competitive; Cell Line; Humans; Ligands; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Naltrexone; Narcotic Antagonists; Oxymorphone; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu

2001
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
    Bioorganic & medicinal chemistry letters, 2009, Mar-15, Volume: 19, Issue:6

    Topics: Binding, Competitive; Chemistry, Pharmaceutical; Drug Design; Humans; Kinetics; Ligands; Molecular Conformation; Molecular Structure; Naltrexone; Narcotic Antagonists; Nitrogen; Peptides; Protein Structure, Tertiary; Receptors, Opioid, mu

2009
Generation of novel radiolabeled opiates through site-selective iodination.
    Bioorganic & medicinal chemistry letters, 2011, Jul-01, Volume: 21, Issue:13

    Topics: Animals; Binding Sites; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Humans; Iodine Radioisotopes; Molecular Structure; Neurotransmitter Agents; Oxymorphone; Radioligand Assay; Receptors, Opioid

2011
Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.
    Bioorganic & medicinal chemistry letters, 2013, Jul-01, Volume: 23, Issue:13

    Topics: Molecular Conformation; Naltrexone; Narcotic Antagonists; Stereoisomerism; Structure-Activity Relationship

2013
Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opio
    Bioorganic & medicinal chemistry, 2013, Nov-01, Volume: 21, Issue:21

    Topics: Amino Acid Sequence; Animals; Binding Sites; Cattle; Humans; Molecular Docking Simulation; Molecular Sequence Data; Mutagenesis, Site-Directed; Naltrexone; Protein Binding; Protein Structure, Tertiary; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Recombinant Proteins; Sequence Alignment

2013